Table of Contents Table of Contents
Previous Page  108 / 916 Next Page
Show Menu
Previous Page 108 / 916 Next Page
Page Background


25th European Congress of Psychiatry / European Psychiatry 41S (2017) S69–S105

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


A pilot project exploring the utility

and acceptability of a socially-assistive

robot in an assessment unit for people

with neuropsychiatric symptoms

S. Loi

1 ,

, R. Khosla


, K. Nguyen


, N. Lautenschlager



D. Velakoulis



University of Melbourne, Psychiatry, Parkville, Australia


Latrobe University, Research Centre for Computers Communication

and Innovation, Bundoora, Australia

Corresponding author.


Socially-assistive robots have been used with older

adults with cognitive impairment in residential care, and found

to improve mood and well-being. However, there is little known

about the potential benefits in adults with other neuropsychiatric



The aim of this project was explore the utility and accept-

ability of a socially-assistive robot in engaging adults with a variety

of neuropsychiatric symptoms.


Betty, a socially-assistive robot was installed in a unit

which specialises in the assessment and diagnosis of adults pre-

senting with neuropsychiatric symptoms. She is 39 cm tall, has a

baby-face appearance and has the ability to engage individuals

through personalised serviceswhich can be programmed according

to individuals’ preferences. These include singing songs and play-

ing games. Training for the nursing staff who were responsible for

incorporating Betty into the unit activities was provided. The fre-

quency, duration and type of activity which Betty was involved in

was recorded. Patients admitted who could provide informed con-

sent were able to be included in the project. These participants

completed pre- and post-questionnaires.


Eight patients (mean age 54.4 years, SD 13.6) who had

diagnoses ranging fromdepression and schizophrenia participated.

Types of activities included singing songs, playing Bingo and read-

ing the news. Participants reported that they were comfortable

with Betty and did not feel concerned in her presence. They enjoyed

interacting with her.


This pilot project demonstrated that participants

found Betty to be acceptable and she was useful in engaging them

in activities. Future directions would involve larger sample sizes

and different settings.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Risperidone-treated children and

adolescents with behavioral

disorders: Do drug dose and patients’

gender and age relate to drug and

metabolite plasma levels?

D. Piacentino

1 , 2 ,

, M. Grözinger


, A. Saria


, F. Scolati



D. Arcangeli


, P. Girardi


, M. Pompili


, A. Conca

2 , 6


NESMOS Department (Neurosciences, Mental Health, and Sensory

Organs), Sapienza University of Rome, School of Medicine and

Psychology, Sant’Andrea Hospital, Rome, Italy


Department of Psychiatry, San Maurizio Hospital, Sanitary Agency

of South Tyrol, Bolzano, Italy


Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Uniklinik

RWTH Aachen, Aachen, Germaany


Experimental Psychiatry Unit, Medizinische Universität Innsbruck,

Innsbruck, Austria


Handicap and Psychological Distress Service, Social Services Agency

of South Tyrol, Bolzano, Italy


Provincial Service of Developmental Psychiatry and Psychotherapy,

Sanitary Agency of South Tyrol, Bolzano, Italy

Corresponding author at: Corresponding author.


Behavioral disorders, such as conduct disorder,

influence choice of treatment and its outcome. Less is known about

other variables that may have an influence.


We aimed to measure the parent drug and

metabolite plasma levels in risperidone-treated children and ado-

lescents with behavioral disorders and investigate the role of drug

dose and patients’ gender and age.


We recruited 115 children/adolescents with DSM-5

behavioral disorders (females = 24; age range: 5–18 years) at the

Departments of Psychiatry of the Hospitals of Bolzano, Italy, and

Innsbruck, Austria. We measured risperidone and its metabolite

9-hydroxyrisperidone plasma levels and the parent drug-to-

metabolite ratio in the plasma of all patients by using LC-MS/MS.

A subsample of 15 patients had their risperidone doses measured

daily. We compared risperidone and 9-hydroxyrisperidone plasma

levels, as well as risperidone/9-hydroxyrisperidone ratio, in males

vs. females and in younger (

14 years) vs. older (15–18 years)

patients by using Mann-Whitney U test. We fitted linear models

for the variables “age” and “daily risperidone dose” by using log-

transformation, regression analysis and applying the R2 statistic.


Females had significantly higher median 9-

hydroxyrisperidone plasma levels (


= 0.000). Younger patients

had a slightly lower median risperidone/9-hydroxyrisperidone

ratio (


= 0.052). At the regression analysis, daily risperidone doses

and metabolite, rather than parent drug–plasma levels were

correlated (R2 = 0.35).


Gender is significantly associatedwithplasma levels,

with females being slower metabolizers than males. Concerning

age, younger patients seem to be rapid metabolizers, possibly due

to a higher activity of CYP2D6. R2 suggests a clear-cut elimination

of the metabolite.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Grey matter volume patterns in

thalamic nuclei are associated with

schizotypy in healthy subjects

P. Di Carlo

1 ,

, G . P


1 , M.


1 , A. B


1 ,

M. Mancini

1 , P. T


1 , G.


2 , A.


1 , G.




University of Bari “Aldo Moro”, Department of Basic Medical

Science, Neuroscience and Sense Organs, Bari, Italy


Bari University Hospital, Psychiatry Unit, Bari, Italy

Corresponding author.


Schizotypy refers to a set of temporally stable traits

that are observed in the general population and that resemble,

in attenuated form, the symptoms of schizophrenia. In a previ-

ous work, we identified volumetric patterns in thalamic subregions

which were associated with disease status, and trained a random

forests classifier, accounting for such thalamic volumetric pat-

terns, that discriminated healthy controls (HC) from patients with

schizophrenia (SCZ) (81% accuracy)

[1] .


i) to assess performance of random forests classifier

developed by Pergola and coworkers

[1] , i

n an independent sam-

ple of healthy subjects; ii) to test whether false positives (FP), i.e.

HC classified as SCZ based on such classifier would be associated

with greater schizotypy compared with true negatives (TN), i.e. HC

classified as such.